Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis.
Dimethyl fumarate for multiple sclerosis.
Masitinib in Patients with Primary Progressive Multiple Sclerosis (PPMS) or Relapse-Free Secondary Multiple Sclerosis (SPMS)
Therapeutic effects of systemic administration of chaperone αB-crystallin associated with binding proinflammatory plasma proteins.
Multiple sclerosis prevalence in the United States commercially insured population.
Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.
Sex hormones and multiple sclerosis: another informative failure.
17 beta-estradiol inhibits cytokine, chemokine, and chemokine receptor mRNA expression in the central nervous system of female mice with experimental autoimmune encephalomyelitis.
Other National MS Societies (Not listed here)
Keystone Symposium: Innate Immunity and Determinants of Microbial Pathogenesis - joint with - Mechanisms of Pro-Inflammatory Diseases
From High- to Low-Frequency Administered Interferon-Beta for Multiple Sclerosis: A Multicenter Study.
Pharmacokinetics and metabolism of mitoxantrone. A review.
Episode 15 with Professor Ludwig Kappos on the DECIDE trial of daclizumab versus interferon ë_-1a
Randomized study combining interferon & glatiramer acetate in multiple sclerosis.
Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients.
Serum IL-33 levels and skin mRNA expression in Behçet's disease.
endMS CONFERENCE
Urinary incontinence in multiple sclerosis: prevalence, severity and impact on patients' quality of life.
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci.
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
8th World Congress on Controversies in Neurology (CONy)
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study.
Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.
Vitamin D3 transactivates the zinc and manganese transporter SLC30A10 via the Vitamin D receptor.
Novel MS Drugs Advance

Pages